Climb Bio receives FDA fast track designation for kidney drug
Tweet Send to a Friend
Climb Bio Inc. (NASDAQ: CLYM) announced the U.S. Food and Drug Administration granted Fast Track Designation to budoprutug for treating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


